

Additional Endoscopic Corpus Biopsy May Increase Accuracy of Helicobacter Pylori Detection

Mohamed E. AbdEllatif MD, PhD

Department of Surgery, Mansoura University Hospital, Egypt, and consultant of laparoscopy and endoscopy HafrElbatin, KSA
surg_latif@hotmail.com

Ahmed Shawqy MD,

Department of Internal Medicine Gastroenterology unit, Mansoura University Hospital, Egypt

Mohamed Abdel Aziz Amer MD, MRCS
(London), Department of General surgery Students' hospital, Mansoura University, Egypt

Hosam Mohammed El-Ghadban, MD

Department of Surgery, Mansoura University Hospital, Egypt

Rania Shahin MD

Department of clinical pathology Benha University Hospital, Egypt and specialist of pathology, HafrElbatin, KSA

Ashraf Abbas MD, PhD,

Department of Surgery, Mansoura University Hospital, Egypt

Ahmed AbdelGhafarSaleh MD

Department of Internal Medicine, gastroenterology unit, Mansoura University Hospital, Egypt

Ahmed Mohamed Husien MD,

Department of Internal Medicine, Benha University Hospital, Egypt

Abstract:

Background: This study was designed to determine if it is important to add corpus biopsies to the routine antral ones for identification of *H. pylori*, especially in case of gastric atrophy and/or intestinal metaplasia.

Methods: This is a prospective multicenter study including three hundred and twenty eight patients with gastritis from June 2014 through Dec.2015. Endoscopic mucosal biopsies from the gastric antrum and corpus were submitted to histological examination according to updated Sydney system for detection of *H.pylori*.

Results: In the study period, a total 328 consecutive patients underwent upper gastrointestinal endoscopy for different reasons. The mean age of the patients was 39 ± 12 years; 183 (55.7%) were women. *H pylori* was found positive in 193 (58.8%) of the patients. Combined antral and corpus biopsies increased the result by 20.8% compared to antral biopsies alone and 4.5% compared to corpus biopsies alone. 20.8% of patients infected with *H pylori* would have been misdiagnosed if testing was based on antrum alone and not combined with corpus. Atrophy and intestinal metaplasia were found in 101(30.8%) and 17(5.2%) of our patients, respectively. Atrophic gastritis was significantly more often in the antrum than the corpus (29.2 VS 11.9%, respectively, $p < 0.05$). Patients with only positive corpus biopsies showed more incidences of both atrophy and intestinal metaplasia. Detection rates of *H pylori* decreased as more as atrophy increased regardless of biopsy site.

Conclusion: This study clarified that additional gastric corpus biopsy to the antral one increases the sensitivity to detect *H pylori* infection especially if associated with gastric atrophy.

Keywords: Gastric atrophy, Sydney system, *H pylori* and Gastritis

1. INTRODUCTION

Helicobacter pylori (*H. pylori*) affect nearly half of the population among the world. It is one of the most frequent and persistent bacterial infections worldwide (1). It is responsible for many of the upper gastrointestinal tract diseases; chronic gastritis, gastrointestinal ulcers, mucosa associated lymphoid tissue lymphoma (MALT) and gastric cancer as well (2). Thus it has been known as "definitive biological carcinogen" by WHO in 1994 (3).

It is already documented that *H. pylori* plays an important role in the promotion of atrophic gastritis. Severe degree of *H. pylori* associated atrophic gastritis is suggested to be an important risk factor in development of gastric carcinoma. Therefore, it is presumed that eradication of *H. pylori* from the stomach is linked to decrease the incidence of gastric cancer development (4).

There are various diagnostic tools to detect *H. pylori* whether invasive (rapid urease test, histology or culture) or non invasive (urea breath test, serology or stool antigen)(5,6). Histological examination despite is invasive, is considered one of the most important diagnostic tests for *H. pylori* infection because it also provides critical information related to the mucosa and presence of associated pathology (7,8).

H. pylori can be seen in hematoxylin and eosin (H&E) stain as gram negative spiral bacteria with sensitivity and specificity as 69-93% and 87-90%, respectively (9). Accuracy can be increased up to 90-100% by using special stains such as modified Giemsa stain, Warthin-Starry silver stain, Genta stain and immune histochemicalstain(10).

H&E stain evaluate the degree of inflammation, atrophy and/or intestinal metaplasia (IM). It can also identify the *H. pylori* in a high magnification field; however, it becomes difficult to see the *H. pylori* when a low density of the organism and atrophic mucosal change are combined. As Giemsa stain is easy to use, inexpensive, and provides good results; it is the slandered method in many laboratories for *H. pylori* detection(11).

Also, Uemura et al. reported that eradication of *H.pylori* decreases the incidence of recurrent gastric cancer in patients underwent endoscopic mucosal resection for early cancer stomach (12). It is widely recommended by many authors that eradication of *H.pylori* is mandatory in case of atrophic gastritis since the atrophy may reverse after successful eradication therapy(13,14). But, it's difficult and challenging the detection of *H.pylori* in case of atrophic gastritis (15). This study was designed to determine if it is important to add corpus biopsies to the routine antral ones for identification of *H. pylori*, especially in case of gastric atrophy and/or intestinal metaplasia

2. METHODS

2.1. Patients

Three hundred and twenty eight patients of uninvestigated dyspepsia, who underwent upper endoscopy were enrolled, (Mansura university hospital - Egypt, Benha University hospital – Egypt, HaferElbatin Central Hospital, KSA) from 2014 through 2015. Patients who received antibiotic or proton pump inhibitor treatment one month beforehand were excluded. All procedures in the study were performed in accordance with the institutional research board (IRB) committee in our institute.

2.2. Study Protocol

All patients underwent upper gastrointestinal endoscopy and two standard gastric biopsies were taken from both antrum (2-3 cm from the pylorus both lesser and greater curvature) and corpus (8-10 cm from the cardia both lesser and greater curvature) for the histological examination (16).

2.3. Histological Examination

Endoscopic biopsies were processed as formalin fixed paraffin embedded tissues, cut into 3-µm thick sections, and then stained with H&E and modified Giemsa stain. These were scored semi-quantitatively according to the updated Sydney classification (Fig 1) (16). The following features were evaluated on each slide, inflammatory activity, glandular atrophy and intestinal metaplasia. According to these histological criteria, there were four grades of atrophy; 0, none; 1, mild; 2, moderate and 3, severe.




Fig1. Sydney Classification for Gastric Biopsy (16)

Additional Endoscopic Corpus Biopsy May Increase Accuracy of Helicobacter Pylori Detection

Presence of polymorphonuclear cell (PNC) infiltration in the specimen refers to activity of the H pylori infection. It is scored based on the density of inflammatory cells in both lamina propria and glandular epithelium (Fig 2). When gastric mucosa is replaced by intestinal epithelium (with goblet cells), it is diagnosed as gastric intestinal metaplasia that is also graded as showed above in Sydney system (Fig 3). Lymphocytes and plasma cell infiltration indicate chronic inflammation associated with H pylori infection (Fig 4). Glandular atrophy is defined as loss of gastric glands that fail to regenerate; the stromal space they previously occupied within the lamina propria is replaced by fibroblasts and extracellular matrix (Fig 5).




Fig2. Antrum Biopsy Showed Moderate Activity (H&E X200)




Fig3. Gastric Biopsy Showed Intestinal Metaplasia (H&E X200)




Fig4. Gastric Biopsy Showed Severe Mononuclear Inflammation with Lymphocytes Follicle Formation (H&E X200)




Fig5. Gastric Biopsy Showed Marked Gastric Atrophy (H&E X100)

2.4. Interpretation of Results

Criteria for positivity and negativity of H pylori were set: Patients were defined positive for H pylori if either one or both was positive with Giemsa stained slides. Patients were considered negative if all specimens were negative. The histological evidence of atrophy was identified when the gastric glands were found decreased in amount and/or widely separated(17).

2.5. Statistics

All data were collected prospectively in an excel file for statistic purposes. We used a student t-test to compare continuous or non parametric variables. While, categorical or parametric variables were compared using Chi-square test. P value less than 0.05 was considered statistically significant. We used the SPSS version 11.5 for statistical analysis (SPSS version 11.5) for windows; SPSS Inc, Chicago, IL, USA).

3. RESULTS

Figure 6 shows the study flow chart for the whole study population. A total of 328 consecutive patients underwent an upper endoscopy procedure during the study period. The mean age of our patients was 39±12 years; 145(44.3%) were men. Upper gastrointestinal endoscopy was indicated for functional dyspepsia in 113(34.5%), epigastric pain in 118(35.9%) or heart burn in 97(29.6%) patients. Endoscopic diagnosis was peptic ulcer disease in 52 (15.9%), gastritis or duodenitis in 173(52.7%), or reflux esophagitis in 103(31.4%) patients. None of our patients were diagnosed with gastric carcinoma. Regardless of the biopsy site, a total of 656 biopsy specimens were received for histological evaluation (Table 1).




Fig6.The patients' flowchart

Additional Endoscopic Corpus Biopsy May Increase Accuracy of Helicobacter Pylori Detection

Table1. Histology Outcomes by Patients' Characteristics

| Variables | N=328 | Both+ve | both -ve | C+veonly | A+veonly |
|------------------------|------------|-----------|----------|----------|----------|
| Gender | | | | | |
| -Male | 215 | 63% | 58% | 62% | 47% |
| -Female | 113 | 37% | 42% | 38% | 53% |
| Age in years | 31±9 | 32±8 | 27±6 | 33±7 | 34±9.5 |
| Endoscopic diagnosis | | | | | |
| -Peptic ulcer | 87 | 33% | 24% | 26% | 29% |
| -Gastritis/duodenitis | 101 | 27% | 29% | 22% | 16% |
| -GERD | 63 | 29% | 18% | 31% | 24% |
| -Normal | 11% | 13% | 21% | 31% | 31% |
| Microscopic findings | | | | | |
| -Atrophy | 101(30.8%) | 43(38.7%) | 19(14%) | 2(13%) | 37 (55%) |
| Corpus and antrum | 34 | 19 | - | - | 13 |
| Antrum only | 62 | 24 | 15 | - | 23 |
| Corpus only | 5 | - | 4 | - | 1 |
| -Intestinal metaplasia | 18(5.5%) | 6(5.4%) | 5(3.7%) | - | 7(10%) |
| Corpus and antrum | 3 | - | 1 | - | 2 |
| Antrum only | 11 | 5 | 4 | - | 2 |
| Corpus only | 4 | 1 | - | - | 3 |

+ve; positive, -ve; negative, A; antrum, C; corpus

H pylori was found positive in 193 (58.8%) of the patients, (Fig 7). In 111 (33.8%) patients, both antral and corpus biopsies were identified positive for H pylori. Combined antral and corpus biopsies increased the result by 20.8% compared to antral biopsies alone and 4.5% compared to corpus biopsies alone. In all patients with positive H pylori, antral biopsies alone were positive in 15 out of 193 (7.7%) patients compared to corpus biopsies which were positive in 67 out of 193 (34.7%).




Fig7. Gastric Biopsy Showed H Pylori Bacterai With in Lumen of Glands (Giemsa Stain With Oil)

In endoscopic diagnosis, atrophy was found in 101(30.8%) of our patients. Atrophic gastritis was significantly more often in the antrum than the corpus (29.2 vs. 11.9%, respectively, $p < 0.05$). Intestinal metaplasia was identified in 17(5.2%) of the patients and antrum was more often than the corpus (4 vs 2% of all patients, respectively). Patients with only positive corpus biopsies showed more incidences of both atrophy and intestinal metaplasia compared with the other possible outcomes, 55 vs. 24.5% for atrophy and 10 vs. 4.6% for metaplasia.(Table 1,2)

Table2. Histopathological Classification of Submitted Biopsies According to Sydney System

| Sites –based biopsy | Score | Activity | Mononuclear inflammation | Metaplasia | Atrophy |
|---------------------|-----------|----------|--------------------------|------------|---------|
| | Variables | | | | |
| | Normal(0) | 128 | 170 | 321 | 289 |
| | Mild (1) | 104 | 74 | 7 | 31 |

| | | | | | |
|--------|--------------|------------|------------|------------|------------|
| Corpus | Moderate (2) | 64 | 54 | 0 | 7 |
| | Severe (3) | 32 | 30 | 0 | 1 |
| Total | | 328 | 328 | 328 | 328 |
| Antrum | Normal(0) | 150 | 182 | 315 | 232 |
| | Mild (1) | 86 | 84 | 7 | 69 |
| | Moderate (2) | 66 | 44 | 6 | 27 |
| | Severe (3) | 26 | 38 | 0 | 5 |
| Total | | 328 | 328 | 328 | 328 |

In biopsies with atrophic gastritis, detection of *H. pylori* in the antrum specimens was inversely correlated with the degree of atrophy. The *H. pylori* positivity in antrum biopsies decreased from 40% within score (0-1) to 18.5% within score (2-3) compared to corpus biopsies (54.6 to 37.5%, respectively). Positivity of *H. pylori* was found significantly more often in the corpus biopsies than in the antrum regardless the degree of atrophy or metaplasia. (Table 3)

Table3. The Sensitivity of Biopsy-Based Test (Histology Giemsa Stain) According to Grade of Mucosal Atrophy

| Positive <i>H. pylori</i> | | | | |
|---------------------------|-------------------------|-------------------------|------------------|----------------------------|
| | Total | 0-1 atrophy | 2-3 atrophy | |
| Antrum | 126(38.5%) | 121/301 (40%) | 5/27(18.5%) | p<0.05 p<0.05 |
| Corpus | 178(54%) | 175/320(54.6%) | 3/8 (37.5%) | |
| | P<0.05 | P<0.05 | P<0.05 | |
| Atrophy | | | | |
| -Antral biopsies | 126/193(65%) | 121/193(62.6%) | 5/193(2.6%) | |
| -Corpus biopsies | 178/193(92.2%) | 175/193(90.6%) | 3/193(1.5%) | |
| -Combined | 193/193(100%) | 189/193(97.9%) | 4/193(2%) | |
| | P<0.05 | P<0.05 | | |

Our results showed that, regardless the gastric biopsy location, as the degree of atrophy increased the prevalence of *H. pylori* infection decreased. Sensitivity of corpus biopsies alone to diagnose *H. pylori* was found significantly higher than the antrum biopsies alone within the same Sydney's score of atrophy (sensitivity of antrum biopsies alone, 65% compared to 92.5% in corpus alone or 100% if combination of both). Prevalence rate of *H. pylori* infection between normal and mild atrophy and moderate or severe atrophy were also evaluated. (Table 3)

4. DISCUSSION

In the clinical setting, it is desirable to find a rapid and cost-effective method for detection of *H. pylori*. There are many methods for detection of *H. pylori* infection (18). Endoscopic mucosal biopsy and histopathology are considered a valuable diagnostic tool for *H. pylori* detection. As well as, it provides a proper evaluation of gastric mucosal changes that have been attributed to chronic *H. pylori* infection i.e. glandular atrophy and/or intestinal metaplasia. It is still widely used as a main diagnostic method in suspicious patients with upper gastrointestinal symptoms or in highly prevalent areas (7). We reported in our study that 193 (58.8%) have been detected to have *H. pylori*. 111(38.8%) patients, both antral and corpus biopsies were identified positive for *H. pylori*. 30.8% of our patients had atrophy in the antrum and/ or corpus or both. Intestinal metaplasia was identified in 17 (5.2%) patients

There is always a debate about the best location of gastric mucosal biopsy that can yield more sensitive detection of *H. pylori* especially in presence of atrophic gastritis (18). In our work; we found that the frequency of *H. pylori* detection in case of gastritis without atrophy or metaplasia was higher with additional corpus biopsy compared with only antrum-based biopsy.

According to Zhang et al (3), and Arimendi-Marillo et al (19), *H. pylori* detection rates were significantly varying depending on the site of the gastric biopsy taken, ranging from 30 % at the antrum lesser curvature to 100% at the corpus greater curvature. Their results were almost comparable to ours in showing that the sensitivity of *H. pylori* detection was 92.2% at corpus while it was 65% at antrum, suggesting that corpus biopsy should be evaluated to detect *H. pylori* infection. Hazell et al (20) also found that it is necessary to evaluate combined biopsies from antrum and corpus. However, other authors reported that antrum biopsy is sufficient to diagnose *H. pylori* gastritis without and morphological changes (21,22)

Our results showed that, regardless the gastric biopsy location, as the degree of atrophy increased the prevalence of H pylori infection decreased. Sensitivity of corpus biopsies alone to diagnose H pylori was found significantly higher than the antrum biopsies alone within the same Sydney's score of atrophy (sensitivity of antrum biopsies alone, 65% compared to 92.5% in corpus alone or 100% if combination of both). Prevalence rate of H pylori infection between normal and mild atrophy and moderate or severe atrophy were also evaluated.

In this study, we found up to 20% of patients with H pylori would be misdiagnosed if H pylori status was based on only antral biopsies. We noticed in our study that patients with only positive corpus biopsies showed more incidences of atrophy and intestinal metaplasia compared with the other possible outcomes. This is explained by the fact that detection of H pylori inversely correlate with the presence of atrophy and as shown from our results that the antrum was the predominant site for atrophy. Therefore, antrum based biopsy only in case of atrophic gastritis yields to more false negative results(23). This finding was in concordance with others (15,24-27). This study clarified that the sensitivity of H pylori detection is decreased in cases of antral atrophic gastritis more than corpus one in the same time as inversely correlated with degree of atrophy.

Our study is not without limitations, the overall number of patients enrolled in the study is not that large number. We did not use urease CLO testor culture test to confirm the diagnosis because these tests are not available in our institutions where the histological examination for H pylori is the routine. Our study was not designed to study the incidence of H pylori infection; it was merely designed to determine the benefit of testing H pylori from two separate gastric sites. So we recommend for another future study to recruit more number of patients. We are currently working on those patients with atrophy and / or intestinal metaplasia to find if their atrophy is reversible after giving the eradication therapy.

5. CONCLUSION

H pylori associated atrophic gastritis decreases sensitivity of detection rates of H pylori. Atrophic changes are predominantly affect antrum first. Adding corpus biopsy to the routine antrum biopsy during endoscopy is recommended for proper evaluation of H pylori infection case of gastric atrophy and to avoid false negative diagnosis.

AUTHOR'S CONTRIBUTION: Mohamed AbdEllatif, Ahmed Mohamed Husien, Ahmed Shawqy, Ahmed AbdelghafarSaleh, Hosam El-Ghadban, Ashraf Abbas, Mohamed Abdel Aziz Amerand Rania Shahin contribute equally in this study.

DISCLOSURE: Drs Mohamed AbdEllatif, Ahmed Mohamed Husien, Ahmed Shawqy, Ahmed AbdelghafarSaleh, Hosam El-Ghadban, Ashraf Abbas, Mohamed Abdel Aziz Amer and Rania Shahin have no conflicts of interest or financial ties to disclose.

ETHICAL STATEMENT: All patients included in this study gave informed written consent after a full explanation of the procedure. All procedures in the study were performed in accordance with the institutional research board (IRB) committee in our institute.

REFERENCES

- [1] Testerman TL, Moris J. Beyond the stomach: An updated view of *Helicobacter pylori* pathogenesis, diagnosis, and treatment. *World J Gastroenterol.* 2014, 28; 20(36): 12781–12808.
- [2] Kuipers EJ. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. *Aliment Pharmacol Ther* 1997;11, 1:71-88.
- [3] Zhang C, Yamada N, Wu YL, Wen M, Matsuhisa T, Matsukura N. Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients. *World J Gastroenterol.* 2005, 21;11(7):976-81
- [4] Ito M, Haruma K, Kamada T. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. *Aliment Pharmacol Ther* 2002; 16: 1449–1456.
- [5] Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol.* 2007; 102:1808–1825.

- [6] Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of *Helicobacter pylori* infection: a systematic review. *Helicobacter*. 2004; 9:347–368.
- [7] Elvira Garza-González, Guillermo Ignacio Perez-Perez, Héctor Jesús Maldonado-Garza and Francisco Javier Bosques-Padilla. A review of *Helicobacter pylori* diagnosis, treatment, and methods to detect eradication. *World J Gastroenterol*. 2014;14; 20(6): 1438-1449
- [8] Aydin O, Egilmez R, Karabacak T, Kanik A. Interobserver variation in histopathological assessment of *Helicobacter pylori* gastritis. *World J Gastroenterol* 2003;9:2232-5
- [9] Kuipers EJ. *Helicobacter pylori* and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. *Aliment Pharmacol Ther* 1997; 11, 1:71-88.
- [10] Fallone CA, Loo VG, Lough J, Barkun AN. Hematoxylin and eosin staining of gastric tissue for the detection of *Helicobacter pylori*. *Helicobacter* 1997; 2:32-5.
- [11] Laine L, Lewin DN, Naritoku W, Cohen H. Prospective comparison of H&E, Giemsa, and Genta stains for the diagnosis of *Helicobacter pylori*. *Gastrointest Endosc* 1997;45:463-7
- [12] Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of *Helicobacter pylori* eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. *Cancer Epidemiol Biomarkers Prev* 1997; 6: 639–42.
- [13] Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007;56:772-781
- [14] Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, Johnstone I, Parsonnet J. *Helicobacter pylori* eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. *Cancer Epidemiol Biomarkers Prev* 2004;13:4-10.
- [15] Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, Virtamo J, Haapiainen R, Rautelin H. Spontaneous disappearance of *Helicobacter pylori* antibodies in patients with advanced atrophic corpus gastritis. *APMIS* 2003;111:619-624.
- [16] Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. *Am J Surg Pathol* 1996.
- [17] Sudraba A, Daugule I, Rudzite D, Funka K, Tolmanis I, Engstrand L, Janciauskas D, Jonaitis L, Kiudelis G, Kupcinskis L, Ivanauskas A, Leja M. Performance of Routine *Helicobacter pylori* Tests in Patients with Atrophic Gastritis. *J Gastrointest Liver Dis* 2011. 20;4, 349-354.
- [18] Tonkic A, Tonkic M, Lehours P, Mégraud F. Epidemiology and diagnosis of *Helicobacter pylori* infection. *Helicobacter*. 2012;17,1:1-8
- [19] Arismendi-Morillo G1, Hernández I, Mengual E, Abreu N, Molero N, Fuenmayor A, Romero G, Lizarrábal M. Gastric cancer risk estimate in patients with chronic gastritis associated with *Helicobacter pylori* infection in a clinical setting. *Rev Gastroenterol Mex*. 2013;78(3):135-43.
- [20] Hazell SL, Hennessy WB, Borody TJ, Carrick J, Ralston M, Brady L, Lee A. *Campylobacter pyloridis* gastritis II: Distribution of bacteria and associated inflammation in the gastroduodenal environment. *Am J Gastroenterol* 1987; 82:297-301?
- [21] Dursun M, Yilmaz S, Yükselen V, Kiliç N, Canoruç F, Tuzcu A. Evaluation of optimal gastric biopsy site and numbers for *H. pylori*, gastric atrophy. *Hepatogastro-enterology*. 2004;51 (60):1732-5.
- [22] Genta RM, Graham DY. Comparison of biopsy sites for the histopathologic diagnosis of *Helicobacter pylori*: a topographic study of *H. pylori* density and distribution. *Gastrointest Endosc* 1994;40:342-5
- [23] Kim CG, Choi IJ, Lee JY, Cho SJ, Nam BH, Kook MC, Hong EK, Kim YW: Biopsy site for detecting *Helicobacter pylori* infection in patients with gastric cancer. *J Gastroenterol Hepatol* 2009, 24:469-474
- [24] Kang HY, Kim N, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Progression of atrophic gastritis and intestinal metaplasia drives *Helicobacter pylori* out of the gastric mucosa. *Dig Dis Sci* 2006;51:2310-5
- [25] Satoh K, Kimura K, Takimoto T, Kihira K. A follow up study of atrophic gastritis and intestinal metaplasia after eradication of *Helicobacter pylori*. *Helicobacter* 1998; 3: 236–40.

Additional Endoscopic Corpus Biopsy May Increase Accuracy of Helicobacter Pylori Detection

- [26] Yoo JY, Kim N, Park YS, Hwang JH, Kim JW, Jeong SH, Lee HS, Choe C, Lee DH, Jung HC, Song IS. Detection rate of Helicobacter pylori against a background of atrophic gastritis and/or intestinal metaplasia. *J Clin Gastroenterol* 2007; 41:751-5.
- [27] Lan HC, Chen TS, Li AF, Chang FY, Lin HC. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. *BMC Gastroenterol*. 2012 Dec 29;12:182